SCHEDULE: Wellington Management Boosts Apellis Stake to 10.9%

Wellington Management Group and its affiliates reported an increased beneficial ownership of 10.87% in Apellis Pharmaceuticals, Inc., holding 13,750,547 common shares.

Summary

• Wellington Management Group LLP and its affiliates reported beneficial ownership of 13,750,547 shares of Apellis Pharmaceuticals, Inc. common stock.
• This aggregate amount represents 10.87% of the class of securities.
• The filing is an Amendment No. 10 to a Schedule 13G, indicating an update to a previously reported significant stake.
• The event date requiring this filing was October 31, 2025.
• Wellington Management Company LLP, an investment adviser, holds shared voting power over 12,982,634 shares and shared dispositive power over 13,320,177 shares.
• The securities are owned of record by clients of one or more investment advisers identified as directly or indirectly owned by Wellington Management Group LLP.
• Vanguard Health Care Fund is identified as a client with an interest relating to more than five percent of this class of securities.

Sentiment

Score: 7

Explanation: The filing indicates a significant and continued institutional investment by Wellington Management Group and its affiliates in Apellis Pharmaceuticals, which is generally viewed as a positive signal of investor confidence. No negative information is presented.

Positives

• A major institutional investor, Wellington Management Group LLP and its affiliates, maintains a significant stake of 10.87% in Apellis Pharmaceuticals, Inc., indicating continued confidence.
• The beneficial ownership of 13,750,547 shares by Wellington Management Group LLP and its affiliates suggests a substantial long-term investment.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or outlook.

Industry Context

This filing indicates continued institutional interest in Apellis Pharmaceuticals, a biotechnology company. Large institutional holdings are common in the pharmaceutical and biotech industries, reflecting long-term investment strategies in companies with promising drug pipelines and market potential.

Comparison to Industry Standards

• The reported 10.87% beneficial ownership by Wellington Management Group and its affiliates is a substantial stake, positioning them as a significant institutional holder in Apellis Pharmaceuticals, Inc. This level of ownership is typical for major asset managers investing in established or growing biotechnology firms.

Stakeholder Impact

• Shareholders: Increased institutional ownership may provide stability and signal confidence in the company's long-term prospects, potentially influencing market perception positively.
• Company Management: Awareness of a significant institutional holder may influence strategic decisions and communication, as large investors often engage with management on corporate governance and strategy.

Key Dates

Recommendation

The Schedule 13G filing primarily discloses a significant institutional ownership stake by Wellington Management Group and its affiliates in Apellis Pharmaceuticals. While the substantial 10.87% holding indicates confidence from a major investor, this filing alone does not provide sufficient fundamental or operational details to warrant a 'buy' or 'sell' recommendation. For existing shareholders, the continued large stake by a reputable institution supports a 'hold' position, suggesting no immediate reason to divest based solely on this ownership disclosure. New investors would require a deeper analysis of the company's financials, pipeline, and market position.

Keywords

Apellis Pharmaceuticals, Wellington Management, Schedule 13G, Common Stock, Institutional Ownership, Biotech, Pharmaceutical, Investment